The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: Outcome of a double-blind randomized placebo-controlled trial

British Journal of Dermatology

Volumn 172, Issue 3, 2015, Pages 677-683

  Karsai, S ^a,b   Friedl, H ^a   Buhck, H ^c   Junger M ^b   Podda, M ^a,d  

^a Department of Dermatology ^*  (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c Office of Biomedical Statistics   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

AGED; ANATOMICAL VARIATION; ARTICLE; BASAL CELL CARCINOMA; BLISTER; CANCER REGRESSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; PULSED DYE LASER; PURPURA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCAR FORMATION; SHAM PROCEDURE; THERAPY EFFECT; VERY ELDERLY; CARCINOMA, BASAL CELL; DYE LASER; SKIN NEOPLASMS; THERAPEUTIC USE; TREATMENT OUTCOME;

AGED; CARCINOMA, BASAL CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LASERS, DYE; MALE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84925293030     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13266     Document Type: Article

References (24)

1. Holterhues C, Vries E, Louwman MW, et al,. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130: 1807-12.
2. Flohil SC, Seubring I, van Rossum MM, et al,. Trends in basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013; 133: 913-18.
3. Arits AH, Schlangen MH, Nelemans PJ, et al,. Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol 2011; 25: 565-9.
4. Hauschild A, Breuninger H, Kaufmann R, et al,. Brief S2k guidelines-basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2013; 11 (Suppl. 3): 10-15.
5. Allison KP, Kiernan MN, Waters RA, et al,. Pulsed dye laser treatment of superficial basal cell carcinoma: realistic or not? Lasers Med Sci 2003; 18: 125-6.
6. Campolmi P, Mavilia L, Bonan P, et al,. 595 nm pulsed dye laser for the treatment of superficial basal cell carcinoma. Lasers Med Sci 2005; 20: 147-8.
7. Campolmi P, Troiano M, Bonan P, et al,. Vascular based non conventional dye laser treatment for basal cell carcinoma. Dermatol Ther 2008; 21: 402-5.
8. Shah SM, Konnikov N, Duncan LM, et al,. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med 2009; 41: 417-22.
9. Tannous Z, Konnikov N, Jarell A,. Response and one year follow up of basal cell carcinomas treated with pulsed dye laser. Lasers Surg Med 2010; 42 (Suppl. 22):37.
10. Ballard CJ, Rivas MP, McLeod MP, et al,. The pulsed dye laser for the treatment of basal cell carcinoma. Lasers Med Sci 2011; 26: 641-4.
11. Konnikov N, Avram M, Jarell A, Tannous Z,. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med 2011; 43: 72-8.
12. Tran HT, Lee RA, Oganesyan G, et al,. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med 2012; 44: 459-67.
13. Minars N, Blyumin-Karasik M,. Treatment of basal cell carcinomas with pulsed dye laser: a case series. J Skin Cancer 2012; 2012: 286480.
14. Sterry W,. Guidelines: the management of dermatopathology. Eur J Dermatol 2006; 16: 476-8.
15. Raasch BA, Buettner PG, Garbe C,. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol 2006; 155: 401-7.
16. Arits AH, Mosterd K, Essers BA, et al,. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single-blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-54.
17. Roozeboom MH, Arits AH, Nelemans PJ, et al,. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012; 167: 733-56.
18. Szeimies RM, Ibbotson S, Murrell DF, et al,. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm) with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-11.
19. Marks R, Owens M, Walters SA,. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Arch Dermatol 2004; 140: 1284-5.
20. Ezughah FI, Dawe RS, Ibbotson SH, et al,. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatol Treat 2008; 19: 111-17.
21. Basset-Seguin N, Ibbotson SH, Emtestam L, et al,. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-53.
22. Weston A, Fitzgerald P,. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 2004; 22: 1195-208.
23. Leibovitch I, Huilgol SC, Selva D, et al,. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53: 445-51.
24. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.